Shots:
- The EC has approved Kisunla to treat early symptomatic Alzheimer’s disease in adults with mild impairment or dementia & confirmed amyloid pathology who are ApoE4 heterozygotes or non-carriers
- Approval was based on P-III (TRAILBLAZER-ALZ 2) study (n=1736, ≥18mos.) & P-IIIb (TRAILBLAZER-ALZ 6) trial (n=843, 60-85yrs.) assessing Kisunla (QM) vs PBO in AD pts
- The TRAILBLAZER-ALZ 2 trial showed Kisunla slowed cognitive & functional decline, while TRAILBLAZER-ALZ 6 supported a gradual titration dosing that reduced ARIA-E at 24/52wks. yet maintained comparable amyloid plaque removal & P-tau217 reduction
Ref: Eli Lilly | Image: Eli Lilly| Press Release
Related News:- Eli Lilly Reports P-III (BRUIN CLL-313) Trial Data on Jaypirca for 1L Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
